New applications of disease genetics and pharmacogenetics to drug development

Highlights • A variable polyT variation within TOMM40 was associated with MCI-AD. • TOMM40 genotypes are 97% informative for estimating age of onset risk. • TOMMORROW is a Phase III delay of onset of MCI-AD in 65–83 year olds. • Pioglitazone has a large safety experience and used in TOMMORROW. • TOM...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Current opinion in pharmacology 2014-02, Vol.14, p.81-89
Hauptverfasser:	Roses, Allen D, Saunders, Ann M, Lutz, Michael W, Zhang, Nanyin, Hariri, Ahmad R, Asin, Karen E, Crenshaw, Donna G, Budur, Kumar, Burns, Daniel K, Brannan, Stephen K
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Algorithms Alzheimer Disease - genetics Alzheimer Disease - prevention & control Animals Brain - pathology Clinical Trials, Phase III as Topic - methods Cognitive Dysfunction - genetics Cognitive Dysfunction - prevention & control Drug Design Genotype Humans Internal Medicine Medical Education Pharmacogenetics Thiazolidinediones - administration & dosage Thiazolidinediones - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • A variable polyT variation within TOMM40 was associated with MCI-AD. • TOMM40 genotypes are 97% informative for estimating age of onset risk. • TOMMORROW is a Phase III delay of onset of MCI-AD in 65–83 year olds. • Pioglitazone has a large safety experience and used in TOMMORROW. • TOMM40, APOE and age are used to stratify the aged normal population.
ISSN:	1471-4892 1471-4973
DOI:	10.1016/j.coph.2013.12.002